X

Trial Profile

Phase II study of lapatinib plus capecitabine for the HER2 overexpressing metastatic breast cancer patients pretreated with oral-FU agents.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 12 May 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Capecitabine (Primary) ; Lapatinib (Primary)
Indications Advanced breast cancer
Focus Biomarker; Therapeutic Use

Most Recent Events

08 Sep 2011 Planned end date changed from 1 Aug 2011 to 1 Aug 2012 as reported by University Hospital Medical Information Network - Japan.
08 Sep 2011 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
11 Sep 2009 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com